Refine by
Cell Isolation Equipment Supplied In Canada
6 equipment items found
Manufactured by:RepliCel Life Sciences based inVancouver, BRITISH COLUMBIA (CANADA)
RCH-01 is a proprietary autologous cell therapy being developed to treat pattern baldness.* *This product is currently in clinical testing and not yet commercially available. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. Though several ...
Manufactured by:RepliCel Life Sciences based inVancouver, BRITISH COLUMBIA (CANADA)
RCS-01 is a proprietary autologous cell therapy being developed to rejuvenate aging or UV-damaged skin.* *This product is currently in clinical testing and not yet commercially available. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells - a type of fibroblast cell - isolated ...
Manufactured by:RepliCel Life Sciences based inVancouver, BRITISH COLUMBIA (CANADA)
RCT-01 is a proprietary autologous cell therapy being developed to treat chronically damaged tendons. * *This product is currently in clinical testing and not yet commercially available. RCT-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells - a type of fibroblast cell - isolated ...
Manufactured by:Stemcell Technologies Inc based inVancouver, BRITISH COLUMBIA (CANADA)
ALDEFLUOR kit for the identification, evaluation and isolation of stem and progenitor cells expressing high levels of ALDH. Size 1 ...
Manufactured by:CanaQuest Medical Corp. based inMississauga, ONTARIO (CANADA)
Clinical testing on humans can only begin after a pre-clinical phase, involving laboratory studies (in vitro) and tests on animals, which has shown that the experimental drug is considered safe and effective. However, no animal is sufficiently similar to humans (even genetically modified ones) to make human testing unnecessary. For this reason, the experimental drug must also be tested on humans. ...
Manufactured by:Hemostemix Inc. based inCalgary, ALBERTA (CANADA)
Hemostemix’s technology uses a patient’s own cells to treat that patient’s disease. The cornerstone of this autologous technology is a novel cell population within the blood called the synergetic cell population (SCP). The synergetic cell population, which can be collected from a simple blood draw, consists of ...